Ointment vehicle
Sponsors
Healthpoint, Pfizer, LEO Pharma, Bayer
Conditions
Alopecia AreataHealthyPsoriasisPsoriasis Vulgaris
Phase 1
Clinical Evaluation of the Photoallergy Potential of Xenaderm Ointment
CompletedNCT00645164
Start: 2008-03-31End: 2008-06-30Updated: 2010-06-08
BAY1003803 Single and Multiple Dose Escalation, Safety, Tolerability and Pharmacokinetics Study
TerminatedNCT02936492
Start: 2016-10-24End: 2017-10-16Updated: 2017-11-08
Phase 2
Safety and Efficacy Study of A Novel Ointment to Treat Plaque Type Psoriasis
CompletedNCT00755196
Start: 2008-09-30End: 2008-12-31Updated: 2017-03-06
AN2728 Topical Ointment to Treat Mild-to-Moderate Plaque-Type Psoriasis
CompletedNCT01300052
Start: 2011-01-26End: 2011-06-06Updated: 2017-04-17
LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris
CompletedNCT01536886
Start: 2012-05-31End: 2012-11-30Updated: 2025-03-07
Efficacy of Twice Daily Application of LEO 124249 Ointment 30 mg/g for 12 Weeks on Eyebrow Alopecia Areata.
TerminatedNCT03325296
Start: 2017-10-30End: 2018-05-16Updated: 2025-02-24